PWPS
CRNX icon

Pinnacle Wealth Planning Services’s Crinetics Pharmaceuticals CRNX Stock Holding History

Pinnacle Wealth Planning Services’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.9K Buy
190
+135
+245% +$6.03K ﹤0.01% 2147
2025
Q4 		$2.56K Buy
+55
New +$2.45K ﹤0.01% 2429

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Pinnacle Wealth Planning Services's CRNX Position: Q1 2026 in Review

Pinnacle Wealth Planning Services increased its Crinetics Pharmaceuticals (CRNX) stake by 245% in Q1 2026, buying an estimated $6.03K and bringing the position to 190 shares worth $6.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2147.

Pinnacle Wealth Planning Services first reported a position in CRNX in Q4 2025 and has held it in 2 quarters since. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Pinnacle Wealth Planning Services held 190 shares of Crinetics Pharmaceuticals worth $6.9K as of Q1 2026.
  • Pinnacle Wealth Planning Services bought 135 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $6.03K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Pinnacle Wealth Planning Services's portfolio in Q1 2026, its #2147 holding.
  • Pinnacle Wealth Planning Services first reported a position in Crinetics Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Pinnacle Wealth Planning Services's 13F filing for Q1 2026, filed 11 May 2026.